[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-metastatic-colorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-metastatic-colorectal-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,55,81,105,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100562768","phase-2-evaluation-of-the-safety-and-efficacy-of-treatment-whigh-dose-melphalan-given-directly-into-the-liver-followed-by-treatment-wapproved-cancer-treatment-or-approved-cancer-treatment-alone-in-patients-w-metastatic-colorectal-cancer-wliver-dominant-disease-100562768",false,"NCT06607458","Evaluation of the Safety and Efficacy of Treatment w\u002FHigh Dose Melphalan Given Directly Into the Liver Followed by Treatment w\u002FApproved Cancer Treatment or Approved Cancer Treatment Alone in Patients w\u002F Metastatic Colorectal Cancer w\u002FLiver Dominant Disease","An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan\u002FHDS Followed by Consolidation Treatment With Trifluridine-Tipiracil Plus Bevacizumab Versus Trifluridine-Tipiracil Plus Bevacizumab Alone in Patients With Refractory Metastatic Colorectal Cancer With Liver Dominant Disease","DEL-LIVER","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of metastatic colorectal cancer and histologically or cytologically proven CRC metastases that occupy 50% or less of the liver parenchyma.\n* Patient has liver-dominant metastatic disease. Liver-dominant is defined as the majority of total tumor burden is located in the liver, and the liver lesions are not resectable or treatable with ablation or are associated with extrahepatic disease that makes surgical intervention non-curative.\n* Disease in the liver must be measurable (per RECIST v.1.1 guidelines) by computed tomography (CT) and\u002For magnetic resonance imaging (MRI).\n* If there is evidence of extrahepatic metastatic disease, it is limited, and the life-threatening component of disease is in the liver. Limited extrahepatic disease is defined in this protocol as follows: up to 5 tumor lesions in the lung with longest diameter not greater than 2 cm and\u002For up to 5 lymph nodes that measure 2 cm or less per lesion; solitary lesions definitively treated with no sign of progression in the last 6 months.\n* Scans used to determine eligibility (CT scan of the chest\u002Fabdomen\u002Fpelvis and MRI of the liver) must be performed within 28 days prior to randomization.\n* Previous treatment and progressed on or following, or intolerant to, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and\u002For an anti-EGFR therapy if RAS wild-type.\n* ECOG PS of 0-1 within 14 days prior to randomization.\n\nExclusion Criteria:\n\n* Child-Pugh Class B or C cirrhosis or evidence of clinically significant portal hypertension by history, endoscopy, or radiologic studies (large abdominal varices, prior history of varices by endoscopy).\n* New York Heart Association functional classification II, III or IV or active cardiac condition(s), including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), worsening or new-onset congestive heart failure, significant arrhythmias, or severe valvular disease that create(s) undue risks of undergoing general anesthesia.\n* History or evidence of clinically significant pulmonary disease that precludes the use of general anesthesia.\n* History of bleeding disorders, presence of brain metastases, or other intracranial abnormalities found on baseline radiologic imaging that would put them at risk for bleeding with anti-coagulation.\n* Known varices at risk of bleeding, including medium or large esophageal or gastric varices, active peptic ulcer, or history of recent hemoptysis.\n* Active second malignancy, or has history of recently definitively treated invasive cancer in the past 2 years prior to enrolment with the exception of non-melanoma skin cancer.\n* Peritoneal lesions or large abdominal masses.\n* Use of immunosuppressive drugs.\n* Inability to temporarily stop chronic anti-coagulation therapy.\n* Active bacterial infections with systemic manifestations.\n* Active viral infection, including Hepatitis B and Hepatitis C infection. NOTE: Patients with anti-hepatitis B core antibody (HBc) positive, or hepatitis B surface antigen (HBsAg) but DNA negative are allowed exception(s).\n* Severe allergic reaction to iodine contrast that cannot be controlled by premedication with antihistamines and steroids.\n* History of or known hypersensitivity to melphalan or the components of the melphalan\u002FHDS system.\n* History of known hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia.\n* Uncontrolled endocrine disorder including diabetes mellitus, hypothyroidism, or hyperthyroidism.\n* Received anti-cancer therapy including radiotherapy or investigational agent for any indication ≤ 30 days prior to randomization\n* Previous treatment with trifluridine-tipiracil.\n* History of allergic reactions attributed to compounds of similar composition to trifluridine\u002Ftipiracil or any of its excipients.\n* Hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption.\n* History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients.\n* History of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies.\n* Contraindications to bevacizumab, including uncontrolled hypertension, history of active fistula or bowel perforation (unless in the setting of a resected primary), history of CVA or arterial thrombotic event in the last 1 year, or history of venous thrombotic event in the last 30 days.\n* Evidence of hepatic vein or portal vein thrombosis\n* Prior chemoembolization or radioembolization to the liver or prior hepatic arterial infusion therapy","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the liver-directed therapy with high dose chemotherapy works on the disease in the liver. Investigators will compare the use of the liver-directed therapy with high dose chemotherapy followed by approved cancer treatment or approved cancer treatment alone.\n\nParticipants will:\n\n* Undergo up to two liver-directed therapy with high dose chemotherapy procedures followed by approved cancer treatment or take approved cancer treatment alone\n* Visit clinic at least every two weeks for checkups and tests\n* Complete scans approximately every two months",[27],"Refractory Metastatic Colorectal Cancer",[29,30,31,32,33,34,35,36,37,38,39,40,41],"melphalan\u002FHDS","melphalan\u002Fhepatic delivery system","trifluridine-tipiracil","trifluridine-tipiracil (FTD-TPI)","trifluridine-tipiracil (FTD-TPI) plus bevacizumab","trifluridine-tipiracil plus bevacizumab","hepatic delivery system","melphalan","liver dominant disease","colorectal cancer","metastatic colorectal cancer","refractory metastatic colorectal cancer","rectal cancer","RECRUITING","2026-05-28",{"date":45,"type":46},"2026-06-01","ACTUAL",{"date":48,"type":46},"2025-08-05",{"date":50,"type":21},"2027-10",{"name":52,"class":53},"Delcath Systems Inc.","INDUSTRY",14,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100620698","phase-3-a-phase-ibiii-study-of-suvemcitug-plus-ftdtpi-in-participants-with-refractory-metastatic-colorectal-cancer-100620698","NCT07361003","A Phase Ib\u002FIII Study of Suvemcitug Plus FTD\u002FTPI in Participants With Refractory Metastatic Colorectal Cancer","A Phase Ib\u002FIII Study of Suvemcitug Plus Trifluridine\u002FTipiracil Tablets (FTD\u002FTPI) Versus Placebo Plus Trifluridine\u002FTipiracil Tablets in Participants With Refractory Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* 1\\. Confirmed by histological and\u002For cytological examination as unresectable metastatic colon or rectal adenocarcinoma;\n* 2\\. At least one measurable tumor lesion (RECIST v1.1);\n* 3\\. Previously received fluorouracil, oxaliplatin, and irinotecan based chemotherapy; had previously undergone or was unsuitable for anti-VEGF therapy. (For participants with RAS wild-type, had previously undergone or was unsuitable for anti-EGFR therapy.);\n* 4\\. Refractory metastatic colorectal cancer having progressed on or are intolerant to the last systemic treatment;\n* 5\\. Good organ and bone marrow function (no administration of hematopoietic growth factors, blood transfusion, or platelets within 14 days before screening hematology test);\n* 6\\. RAS mutation status confirmed by testing tumor tissue and \u002For blood sample.\n\nExclusion Criteria:\n\n* 1\\. Having a second active primary malignancy within the past 5 years;\n* 2\\. Symptomatic central nervous system (CNS) metastases or CNS metastases requiring local CNS-directed therapy (e.g., radiotherapy or surgery) or corticosteroid treatment within 2 weeks prior to the first administration of the study treatment;\n* 3\\. Any active infection requiring systemic treatment within 2 weeks prior to the initiation of the study treatment;\n* 4\\. Pleural effusion, pericardial effusion, or ascites that is uncontrolled or has required drainage or medical intervention within 4 weeks prior to the first administration of the study treatment;\n* 5\\. Received systemic immuno suppressive therapy within 4 weeks prior to randomization (excluding prophylactic use or chronic low-dose steroids \\[≤20 mg\u002Fday prednisone equivalent dose\\]);\n* 6\\. Currently taking or has recently taken (within 10 days prior to the first dose) aspirin (\\>325 mg\u002Fday);\n* 7\\. Active or chronic hepatitis B (HBsAg or HBcAb positive and HBV DNA≥2000 IU\u002FmL or ≥10000 copies\u002FmL) or hepatitis C infection (HCV antibody positive and HCV RNA≥ULN);\n* 8\\. Clinically significant cardiovascular disease within 6 months prior to the first administration of the study treatment;symptomatic coronary artery disease requiring medication; arrhythmia requiring medication (excluding asymptomatic atrial fibrillation with controlled ventricular rate); QTcF interval \\>470 ms at rest state; or uncontrolled hypertension or pulmonary hypertension;\n* 9\\. Known hereditary or acquired bleeding and thrombotic tendencies (e.g., hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.); clinically significant bleeding events, arterial or deep venous thrombotic events, or superficial venous thrombosis and intermuscular venous thrombosis requiring intervention within 6 months prior to enrollment;\n* 10\\. Participants with proteinuria (urine protein \\>2+ found during screening examinations; or urine protein 2+ with 24-hour urine protein quantification ≥1g\u002F24h);\n* 11\\. Participants with a history of intestinal obstruction (including incomplete intestinal obstruction) within 1 month prior to enrollment; participants with a history of abdominal fistula, gastrointestinal perforation, or abdominal abscess.",{"count":63,"type":21},464,[65],"PHASE3","The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine\u002Ftipiracil tablets in colorectal cancer participants.\n\nThe primary goal of Phase III Study is to evaluate the efficacy of Suvemcitug in combination with trifluridine\u002Ftipiracil tablets in colorectal cancer participants. Researchers will compare Suvemcitug + trifluridine\u002Ftipiracil tablets with placebo (a look-alike substance that contains no drug)+ trifluridine\u002Ftipiracil tablets to see if Suvemcitug + trifluridine\u002Ftipiracil tablets works better in treating refractory metastatic colorectal cancer.",[27],[40,69,70],"Suvemcitug","trifluridine\u002Ftipiracil","2026-01-14",{"date":73,"type":46},"2026-01-22",{"date":75,"type":46},"2025-11-12",{"date":77,"type":21},"2028-07",{"name":79,"class":53},"Jiangsu Simcere Pharmaceutical Co., Ltd.",6,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":104},"100613063","phase-2-trifluridinetipiracil-plus-fruquintinib-vs-trifluridinetipiracil-plus-bevacizumab-in-refractory-metastatic-colorectal-cancer-a-randomized-controlled-open-label-non-inferiority-trial-100613063","NCT07261709","Trifluridine\u002FTipiracil Plus Fruquintinib vs. Trifluridine\u002FTipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial","Inclusion Criteria:\n\n1. All study participants must sign the informed consent form before any study-related procedures are initiated.\n2. Aged 18-75 years, both males and females.\n3. Histologically confirmed unresectable colorectal cancer.\n4. RAS status known (mutant or wild-type).\n5. Progression or intolerance after at least two prior systemic regimens that must have contained fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy plus anti-VEGF therapy and\u002For anti-EGFR therapy.\n6. At least one measurable lesion per RECIST v1.1.\n7. Able to swallow oral tablets or capsules.\n8. Estimated life expectancy ≥ 12 weeks.\n9. ECOG performance status 0-1.\n10. Adequate major organ function (within 7 days before randomization):\n\n    Absolute neutrophil count ≥ 1.5 × 10⁹\u002FL Platelet count ≥ 75 × 10⁹\u002FL Hemoglobin ≥ 90 g\u002FL (no transfusion within 7 days) Creatinine clearance ≥ 60 mL\u002Fmin (Cockcroft-Gault formula) Total bilirubin ≤ 1.5 × upper limit of normal (ULN) AST and ALT ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases present) Urinalysis showing proteinuria ≤ 1+ or 24-h urine protein \\\u003C 1 g INR or PT ≤ 1.5 × ULN (acceptable if on anticoagulation and PT within intended therapeutic range)\n11. Women of child-bearing potential must have a negative serum pregnancy test within 7 days before randomization; all participants and their partners must agree to use highly effective contraception from screening through at least 6 months after the last dose of study medication.\n\nExclusion Criteria:\n\n* 1.Prior treatment with trifluridine\u002Ftipiracil, fruquintinib, or any other VEGF-receptor tyrosine-kinase inhibitor (e.g., apatinib, regorafenib, anlotinib).\n\n  2.Pregnant or lactating women, or women who may become pregnant during the study.\n\n  3.Anti-cancer therapy given ≤ 4 weeks before randomization (or not yet completed).\n\n  4.Clinically relevant non-haematological CTCAE grade ≥ 3 toxicity from prior anti-cancer therapy that has not resolved to ≤ grade 1 (except alopecia and skin pigmentation).\n\n  5.Symptomatic central-nervous-system metastases, unstable neurological status, or requirement for an increased steroid dose to control CNS disease.\n\n  6.Severe or uncontrolled acute or chronic active infection. 7.History of active or interstitial lung disease, pneumonitis, or pulmonary arterial hypertension.\n\n  8.Clinically significant active hepatitis of any cause, including but not limited to hepatitis B or C.\n\n  9.Known HIV-positive status. 10.Uncontrolled hypertension (systolic BP ≥ 150 mmHg and\u002For diastolic BP ≥ 100 mmHg), uncontrolled arrhythmia, or symptomatic arrhythmia.\n\n  11.Arterial thrombo-embolic event ≤ 6 months before randomization, including cerebrovascular accident or myocardial infarction.\n\n  12.Major surgery ≤ 4 weeks before randomization (surgical incision must be fully healed before study drug administration), not yet recovered from previous surgery, or major surgery anticipated during the study.\n\n  13.Radiotherapy ≤ 2 weeks before randomization, except short-course palliative radiotherapy for symptom relief.\n\n  14.Any other clinically significant medical condition that, in the investigator's opinion, would compromise patient safety or study integrity.\n\n  15.Concurrent or previous malignancy within 5 years, except adequately treated basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix.","75 Years",{"count":89,"type":21},236,[24],"This study is an investigator-initiated, prospective, multicenter, randomized, controlled, open-label, non-inferiority trial designed to evaluate the efficacy and safety of trifluridine\u002Ftipiracil plus fruquintinib versus trifluridine\u002Ftipiracil plus bevacizumab in the treatment of refractory metastatic colorectal cancer.",[27],"NOT_YET_RECRUITING","2025-11-21",{"date":96,"type":46},"2025-12-03",{"date":98,"type":21},"2025-12-01",{"date":100,"type":21},"2028-03-30",{"name":102,"class":103},"Sun Yat-sen University","OTHER",1,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100542457","phase-3-nimotuzumab-combined-with-trifluridinetipiracil-in-the-treatment-of-refractory-metastatic-colorectal-cancer-100542457","NCT06343116","Nimotuzumab Combined With Trifluridine\u002FTipiracil in the Treatment of Refractory Metastatic Colorectal Cancer","Randomized Double-blind, Placebo-controlled, Multicenter Clinical Study of Nimotuzumab Combined With Trifluridine\u002FTipiracil in Third-line and Beyond for the Treatment of Metastatic Colorectal Cancer","NOTABLE-308","Inclusion Criteria:\n\n1. Age 18-75 years old, gender unlimited;\n2. Histologically or cytologically confirmed diagnosis of colorectal cancer (CRC);\n3. Metastatic colorectal cancer, disease progression after previous second-line or above standard therapy;\n4. Efficacy of previous line therapy containing an anti-EGFR agent (panitumumab or cetuximab) with complete or partial response, or disease stable; and more than 4 months from last dose of anti-EGFR agent administered before randomization;\n5. MSS\u002FpMMR status detected by IHC or PCR;\n6. RAS and BRAF wild-type status;\n7. ECOG Performance Status 0-1;\n8. Measurable disease according to RECIST criteria v1.1;\n9. Life expectancy of at least 3 months;\n10. Adequate organ and bone marrow function, defined as follows: hemoglobin≥9.0 g\u002FdL; absolute neutrophil count (ANC)≥1.5×10\\^9\u002FL; white Blood Cell Count≥4×10\\^9\u002FL;platelets≥100×10\\^9\u002FL; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN), patients with liver metastases should be ≤ 5 times the ULN; serum creatinine≤1.5×ULN or estimated creatinine clearance \\> 60 mL\u002Fmin;\n11. Women of childbearing age should have a negative result of serum HCG or urine pregnancy tests within 72 hours prior to randomization (Postmenopausal women who have had amenorrhea for at least 12 months are considered sterile and women known to have had tubal ligation are not required to undergo pregnancy tests) ;\n12. Good compliance and signed informed consent.\n\nExclusion Criteria:\n\n1. Had other malignancies within the past 5 years or at the same time (exceptions include: cured thyroid cancer, non-melanoma skin cancer, carcinoma in situ of the cervix, stage I ductal carcinoma in situ, stage I endometrial cancer or other solid tumors, and effectively treated lymphoma with no evidence of disease for more than 5 years);\n2. Has a serious underlying medical condition that makes it impossible to safely administer the trial treatment. Including but not limited to active infections requiring systemic medication: compensatory heart failure (NYHA grade III and IV), unstable angina, and acute myocardial infarction within 3 months prior to enrollment;\n3. Patients who received trifluridine\u002Ftipiracil or treated with EGFR monoclonal antibody or EGFR tyrosine kinase inhibitor within four months;\n4. Known allergy to prescription or any component of the prescription used in this study;\n5. Women who are pregnant or are breastfeeding;\n6. Has brain metastases or any symptoms of brain metastases\n7. Factors that significantly affect oral drug absorption, such as dysphagia, chronic diarrhea, gastrointestinal obstruction, etc; Uncontrolled Crohn's disease or ulcerative colitis;\n8. Participated in other clinical trials within 4 weeks;\n9. With HIV, HPV, or syphilis infection, or active hepatitis (hepatitis B, hepatitis C)\n10. Other reasons that are not suitable to participate in this study according to the researcher's judgment.",{"count":114,"type":21},420,[65],"This is a randomized, double-blind, placebo-controlled, multicenter study. The main purpose of the study is to evaluate the clinical efficacy and safety of nimotuzumab combined with trifluridine\u002Ftipiracil in third-line and beyond for the treatment of metastatic colorectal cancer (mCRC). This study planned to be divided into two parts: Part A and Part B. Part A (safety run-in) with a 3 + 3 study design, which primary endpoint is safety; Part B (main study) with a prospective, randomized, double-blind, placebo-controlled design, which primary endpoint is overall survival (OS).",[27],[119,70,39],"Nimotuzumab","2024-03-26",{"date":122,"type":46},"2024-04-02",{"date":124,"type":21},"2024-04",{"date":126,"type":21},"2027-04",{"name":128,"class":103},"Biotech Pharmaceutical Co., Ltd.",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":146,"leadSponsor":148,"locationsCount":104},"100515407","amplitude-modulated-radiofrequency-electromagnetic-field-treatment-combined-with-tas-102-lonsurf-and-bevacizumab-in-refractory-metastatic-colorectal-cancer-100515407","NCT05991102","Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer","Live-RF","Inclusion Criteria:\n\n* Written informed consent prior to any study procedure\n* 18 years or older\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Histologically confirmed colorectal cancer\n* Liver metastasis\n* Patients received at least two prior regimens of standard chemotherapies and the patient is refractory to or failing these therapies or is unsuitable for the treatment.Standard chemotherapy includes fluoropyrimidine, oxaliplatin, irinotecan,bevacizumab and for patients with KRAS wild-type tumors at least one anti-EGFR monoclonal antibody of cetuximab\u002Fpanitumumab. Patients with BRAF mutant tumors: BRAF inhibitor, MSI-H patients: Checkpoint-inhibition\n* Knowledge of KRAS status (i.e. wild-type or mutant)\n* Adequate bone-marrow, liver and renal function:\n\n  1. Hemoglobin value of ≥9.0 g\u002FdL.\n  2. Absolute neutrophil count of ≥1,500\u002Fmm3\n  3. Platelet count ≥100,000\u002Fmm3 (IU: ≥100 × 109\u002FL).\n  4. Total serum bilirubin of ≤1.5 mg\u002FdL\n  5. Aspartate aminotransferase and alanine aminotransferase\n\n     ≤3.0 × upper limit of normal (ULN); if liver function abnormalities are due to underlying Liver metastasis, AST and ALT ≤5 × ULN.\n  6. Serum creatinine of ≤1.5 mg\u002FdL.\n* Patient is able to take medications orally\n* Women of childbearing potential with negative pregnancy test and agreement for adequate birth control if conception is possible\n\nExclusion Criteria:\n\n* Significant extrahepatic metastasis\n* Previous treatment with TAS 102\n* Serious illness other than colorectal cancer or serious medical condition:\n\n  1. Other concurrently active malignancies excluding malignancies that are disease free for more than 5 years or carcinoma-in-situ deemed cured by adequate treatment.\n  2. Known brain metastasis or leptomeningeal metastasis.\n  3. Active infection (ie, body temperature ≥38°C due to infection).\n  4. Ascites, pleural effusion or pericardial fluid requiring drainage in last 4 weeks\n  5. Intestinal obstruction, pulmonary fibrosis, renal failure, liver failure, or cerebrovascular disorder\n  6. Uncontrolled diabetes.\n  7. Myocardial infarction within the last 12 months, severe\u002Funstable angina, symptomatic congestive heart failure New York Heart Association (NYHA III\u002FIV)\n  8. Gastrointestinal hemorrhage.\n  9. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or hepatitis B or C.\n  10. Patients with autoimmune disorders or history of organ transplantation who require immunosuppressive therapy.\n  11. Psychiatric disease that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results.\n* Radiofrequency treatment technically not possible (e.g. larger metal implants)\n* Cardiac pacemakers\u002FICD\n* Patient not able for supine positioning (e.g. due to pain)",{"count":137,"type":21},12,[139],"NA","Combined chemotherapy and radiofrequency electromagnetic field treatment for patients with liver dominant refractory metastatic colorectal cancer",[27],"2023-12-15",{"date":144,"type":46},"2023-12-21",{"date":142,"type":46},{"date":147,"type":21},"2026-11",{"name":149,"class":103},"Charite University, Berlin, Germany"]